BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/14/2025 5:49:32 AM | Browse: 104 | Download: 418
 |
Received |
|
2025-05-20 07:05 |
|
Peer-Review Started |
|
2025-05-20 07:06 |
|
First Decision by Editorial Office Director |
|
2025-05-30 00:03 |
|
Return for Revision |
|
2025-05-30 00:45 |
|
Revised |
|
2025-06-02 20:15 |
|
Publication Fee Transferred |
|
2025-06-06 05:18 |
|
Second Decision by Editor |
|
2025-07-01 02:35 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-07-01 07:06 |
|
Articles in Press |
|
2025-07-01 07:06 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-08-01 01:31 |
|
Publish the Manuscript Online |
|
2025-08-14 05:49 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yi-Cong Wang, Chen-Guang Zhang, Yu-Wen Wang, Can Guo, Ting Pan, Peng-Jie Yu, Bao-Jia Cai, Rui-Hua Ding, Jia-Luo Qiang, Chen-Qian Deng, Cheng-Hao Hu and Yong-Huan Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Qinghai Provincial Science and Technology Plan |
2023-ZJ-787 |
|
| Corresponding Author |
Peng-Jie Yu, PhD, Professor, Vice Director, Department of Gastrointestinal Oncology, The Affiliated Hospital of Qinghai University, No. 29 Tongren Road, Xining 810000, Qinghai Province, China. hnypj768@126.com |
| Key Words |
Sintilimab; Gastric cancer; Efficacy; Safety; Neoadjuvant chemotherapy |
| Core Tip |
This study demonstrated that the SOX combined with sintilimab (PD-1 inhibitor) significantly improved long-term survival outcomes in patients with advanced gastric cancer (GC) compared with P-SOX (albumin-bound paclitaxel plus SOX) or SOX alone, with superior 3-year overall survival (48.1% vs 30.5% and 29.0%) and early progression-free survival rates. The regimen also maintains a favorable safety profile, suggesting that it is a promising perioperative treatment option. The key prognostic factors include a tumor diameter ≤ 2 cm, well-differentiated histology, and negative lymph node status. These findings support the integration of immunotherapy into neoadjuvant strategies for locally advanced GC. |
| Publish Date |
2025-08-14 05:49 |
| Citation |
Wang YC, Zhang CG, Wang YW, Guo C, Pan T, Yu PJ, Cai BJ, Ding RH, Qiang JL, Deng CQ, Hu CH, Xu YH. SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety. World J Gastrointest Oncol 2025; 17(8): 109646 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i8/109646.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i8.109646 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
